Loading

Human Immunogenicity/ Immunofunction

Human Artificial Lymph Node (HuALN) Technology

Our HuALN technology enables predictive in vitro testing of immune responses triggered by drug candidates. This 3D matrix-based technology using primary cells emulates in vivo conditions and allows the analyses of immunogenicity, immunofunction and immunotoxicity. It therefore provides a tool to bridge the existing gap between animal-based pre-clinical testing and first-in-man application.

  • Biopharmaceutical drugs bear the risk of unexpected immunogenicity in the patient (e. g. neutralizing antibody formation, sensitization, allergy, or anaphylactic shock)
  • Deficient predictability of animal models for immunofunction and immunotoxicity testing of biological therapeutics in humans
  • 26th Animal Protection Award by Germany‚Äôs Federal Ministry of Food, Agriculture and Consumer Protection in December 2007 for our pioneering HuALN technology
  • Collaboration agreements on proprietary ALN model and related assays with pharma, biochemical, and cosmetic companies

Key advantages of our Human Artificial Lymph Node:

  • Long-term 3D matrix culture
  • Mimics in vivo conditions of the human lymph node 
  • Enables the analyses of immunogenicity, immunofunction and immunotoxicity with high reliability 
  • Risks and efficacies of drug candidates can be determined simultaneously as early as possible in the development
  • Bridges the existing gap between animal-based pre-clinical testing and first-in-man application
  • Is an alternative to animal testing which is especially important for cosmetic substances due to the EU ban on animal testing for investigations on systemic toxicity, effective at the end of 2013